These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17273155)

  • 21. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population.
    Dassanayake AS; Kasturiratne A; Rajindrajith S; Kalubowila U; Chakrawarthi S; De Silva AP; Makaya M; Mizoue T; Kato N; Wickremasinghe AR; de Silva HJ
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1284-8. PubMed ID: 19476560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: diagnosis and treatment of non-alcoholic fatty liver disease.
    Oh MK; Winn J; Poordad F
    Aliment Pharmacol Ther; 2008 Sep; 28(5):503-22. PubMed ID: 18532991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnosis and therapy in NASH].
    Tokushige K
    Rinsho Byori; 2009 Sep; 57(9):848-53. PubMed ID: 19860210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
    Fan JG
    J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatty liver: a novel component of the metabolic syndrome.
    Kotronen A; Yki-Järvinen H
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):27-38. PubMed ID: 17690317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: the treatment of fatty liver disease associated with the metabolic syndrome.
    Marchesini G; Natale S; Manini R; Agostini F
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():37-9. PubMed ID: 16225470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors.
    St George A; Bauman A; Johnston A; Farrell G; Chey T; George J
    J Gastroenterol Hepatol; 2009 Mar; 24(3):399-407. PubMed ID: 19067776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Non alcoholic fatty liver disease assessment].
    Juriens I; Rigaux J; Blero D
    Rev Med Brux; 2012 Sep; 33(4):205-11. PubMed ID: 23091922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Non-alcoholic fatty liver disease can cause permanent liver damage].
    Kechagias S; Ekstedt M
    Lakartidningen; 2012 Nov 14-20; 109(46):2100-4. PubMed ID: 23259217
    [No Abstract]   [Full Text] [Related]  

  • 34. [An update on non-alcoholic fatty liver disease].
    Méndez-Sánchez N; Chávez-Tapia NC; Uribe M
    Rev Invest Clin; 2004; 56(1):72-82. PubMed ID: 15144045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant correlations between severe fatty liver and risk factors for metabolic syndrome.
    Hsiao PJ; Kuo KK; Shin SJ; Yang YH; Lin WY; Yang JF; Chiu CC; Chuang WL; Tsai TR; Yu ML
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2118-23. PubMed ID: 18031368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease and metabolic syndrome: a concise review.
    Streba LA; Cârstea D; Mitruţ P; Vere CC; Dragomir N; Streba CT
    Rom J Morphol Embryol; 2008; 49(1):13-20. PubMed ID: 18273497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.
    Munteanu M; Ratziu V; Morra R; Messous D; Imbert-Bismut F; Poynard T
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):187-91. PubMed ID: 18568141
    [No Abstract]   [Full Text] [Related]  

  • 38. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
    Byrne CD
    Diabet Med; 2012 Sep; 29(9):1098-107. PubMed ID: 22672330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications.
    Tsochatzis EA; Manolakopoulos S; Papatheodoridis GV; Archimandritis AJ
    Scand J Gastroenterol; 2009; 44(1):6-14. PubMed ID: 18661429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is liver disease a threat to patients with metabolic disorders?
    Marchesini G; Forlani G; Bugianesi E
    Ann Med; 2005; 37(5):333-46. PubMed ID: 16179269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.